Gabapentin Capsule
Product Images NDC 80425-0033

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph showing mean pain scores over 8 weeks comparing Gabapentin 3600 mg/day and placebo. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain scores from 0 to 10. Two periods are noted: a 4-week dose titration and a 4-week fixed dose. Gabapentin shows a marked decline in mean pain scores over time, while placebo remains relatively stable.*

FDA Label Image

Fig 2

Line graph showing mean pain scores over seven weeks comparing placebo and two Gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents time in weeks, including a 3-week dose titration and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Both Gabapentin groups demonstrate a greater reduction in pain scores compared to placebo.*

FDA Label Image

Fig 3

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates between placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% response for placebo versus 29% for GBP 3600 mg. Study 2 shows 14% for placebo versus 32% for GBP 1800 mg and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Fig 4

A scatter plot comparing three studies (a, b, and c) on the difference (%) versus daily dose (mg) for Gabapentin. The horizontal axis represents the daily dose ranging from 600 mg to 1800 mg, and the vertical axis shows the difference percentage from 2% to 22%. Data points are marked for each study at 600, 900, 1200, and 1800 mg doses.*

FDA Label Image

Gabapentin 300mg Cap Qty 30 Ndc 80425 0033

Gabapentin 300 mg capsule packaging label by Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0033 and batch information, indicating a quantity of 30 capsules. It also provides storage instructions and a federal law caution about prescription use.*

FDA Label Image

Gabapentin 300mg Cap Qty 40 Ndc 80425 0033

Label for Gabapentin 300 mg capsules, package of 40, by Advanced Rx of Tennessee, LLC. Displays NDC 80425-0033- and includes lot number 40GAB3001221 with expiration 9/30/2023. The label states storage temperature and a comparison to a similar product, VEEGIRONTM.*

FDA Label Image

Gabapentin 300mg Cap Qty 60 Ndc 80425 0033

The packaging label for Gabapentin 300 mg capsules, with a quantity of 60 capsules. The label shows the product is manufactured or labeled by Advanced Rx of Tennessee, LLC and provides a comparison to Neurontin. It includes numeric codes, lot number, expiration date (9/30/2023), storage instructions (20°-25°C), and barcodes for identification.*

FDA Label Image

Gabapentin 300mg Cap Qty 90 Ndc 80425 0033

Gabapentin 300 mg oral capsules packaging label from Advanced Rx of Tennessee, LLC. The label includes product NDC 80425-0033, lot number 90GP300923 with expiration date 9/30/2023, storage instructions, barcode, and caution statement regarding federal law restrictions.*

FDA Label Image

Structure

Chemical structure diagram of gabapentin, showing its molecular framework with a cyclohexane ring, an amino group (CH2NH2), and a carboxyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.